- Conditions
- Gastroenteropancreatic Neuroendocrine Tumor
- Interventions
- Lutathera, Gallium 68 Dotatate, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), PET/CT
- Drug · Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Stanford, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1105–1128
of 1,693
matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy) Clear all
- Conditions
- Metabolism - Cerebral Energy
- Interventions
- Fermented Papaya Preparation, Granulated Sugar
- Drug · Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 65 Years to 100 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma
- Interventions
- Computed Tomography, Magnetic Resonance Imaging, Tazemetostat
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 581
- States / cities
- Anchorage, Alaska • Goodyear, Arizona • Kingman, Arizona + 369 more
- Conditions
- Brain Mass
- Interventions
- MRI with DTI and fMRI
- Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Abiraterone, Biospecimen Collection, Bone Scan, Computed Tomography, Docetaxel, Enzalutamide, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, PSMA PET Scan, Vudalimab
- Drug · Procedure
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Interventions
- 18F-FHBG, Aldesleukin, Cellular Therapy, Computed Tomography, Filgrastim, Laboratory Biomarker Analysis, Lenalidomide, Leukapheresis, Melphalan, Plerixafor, Positron Emission Tomography
- Radiation · Biological · Procedure + 2 more
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Neuroendocrine Tumor
- Interventions
- Computed Tomography, Gallium Ga 68-DOTA-FAPI-04, Positron Emission Tomography
- Procedure · Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Pembrolizumab
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 533
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 340 more
- Conditions
- Genotype, Allelic Frequencies of Genetic Markers, Brain Mapping, Brain Disease, fMRI
- Interventions
- Not listed
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2,802 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1991 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Metastatic Sarcoma, Recurrent Sarcoma, Sarcoma
- Interventions
- Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography, 18F-FDG
- Procedure · Drug · Radiation
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Carcinoma of Unknown Primary
- Interventions
- capecitabine, docetaxel, gemcitabine hydrochloride, positron emission tomography
- Drug · Procedure
- Lead sponsor
- University of Medicine and Dentistry of New Jersey
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 6
- States / cities
- Hamilton, New Jersey • Montclair, New Jersey • Morristown, New Jersey + 3 more
- Conditions
- Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor, Childhood Central Nervous System Teratoma, Childhood Central Nervous System Yolk Sac Tumor, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Central Nervous System Embryonal Tumor, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- oxaliplatin, fluorouracil, leucovorin calcium, pharmacological study, positron emission tomography, computed tomography
- Drug · Other · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hyperparathyroidism, Primary
- Interventions
- 18F-Fluorocholine, Positron Emission Tomography (PET)
- Drug · Procedure
- Lead sponsor
- Thomas Hope
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- High Grade Glioma, MGMT-Unmethylated Glioblastoma, MGMT-Methylated Glioblastoma
- Interventions
- DB107-RRV, DB107-FC, Radiation Therapy (RT), Temozolomide, Magnetic Resonance Imaging (MRI), Surgical resection
- Genetic · Drug · Radiation + 1 more
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2042
- U.S. locations
- 5
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 2 more
- Conditions
- Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
- Interventions
- Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Docetaxel, Gemcitabine, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Questionnaire Administration, Sacituzumab Govitecan
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 162
- States / cities
- Phoenix, Arizona • Irvine, California • Orange, California + 127 more
- Conditions
- Recurrent Plasma Cell Myeloma, Plasma Cell Myeloma, Secondary Amyloidosis
- Interventions
- Daratumumab, Imaging Agent, Positron Emission Tomography, Pharmacological Study
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, CT-guided Stereotactic Body Radiation Therapy, Intrafraction Motion Monitoring, Magnetic Resonance Imaging, Questionnaire Administration
- Procedure · Radiation · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2036
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- HER2 Positive Breast Carcinoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Interventions
- Copper Cu 64-DOTA-Trastuzumab, Laboratory Biomarker Analysis, Pertuzumab, Positron Emission Tomography, Therapeutic Conventional Surgery, Trastuzumab
- Radiation · Other · Biological + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Retinopathy of Prematurity, Neurodevelopmental Disorders, Macular Edema
- Interventions
- Swept Source OCT, Magnetic Resonance Imaging, Scavenged blood collection
- Device · Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 30 Weeks and older
- Enrollment
- 191 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2021
- U.S. locations
- 4
- States / cities
- Gainesville, Florida • St Louis, Missouri • Durham, North Carolina + 1 more
- Conditions
- Cognitive Ability, General
- Interventions
- Cognitive Training - 48 sessions, Fitness, Active Control, active tDCS, sham tDCS, Cognitive Training - 20 sessions
- Behavioral · Device
- Lead sponsor
- University of Illinois at Urbana-Champaign
- Other
- Eligibility
- 18 Years to 44 Years
- Enrollment
- 521 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Urbana, Illinois
- Conditions
- Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma
- Interventions
- Atezolizumab, Biopsy, Biospecimen Collection, Computed Tomography, Glycosylated Recombinant Human Interleukin-7, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Positron Emission Tomography and Computed Tomography Scan
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 9
- States / cities
- Riverside, California • Tampa, Florida • Honolulu, Hawaii + 5 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- chemotherapy, conventional surgery, magnetic resonance imaging, magnetic resonance spectroscopic imaging, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Lip and Oral Cavity Carcinoma, Metastatic Nasal Cavity Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Pharyngeal Squamous Cell Carcinoma, Metastatic Sinonasal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Pharyngeal Squamous Cell Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
- Interventions
- Atezolizumab, Bevacizumab, Biospecimen Collection, Carboplatin, Cetuximab, Cisplatin, Computed Tomography, Docetaxel, Echocardiography Test, Magnetic Resonance Imaging, Positron Emission Tomography
- Biological · Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 172
- States / cities
- Little Rock, Arkansas • Dublin, California • Emeryville, California + 135 more
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Unresectable Melanoma
- Interventions
- Biospecimen Collection, Cyclophosphamide, Echocardiography, Fludarabine, Interleukin-2, Lifileucel, Magnetic Resonance Imaging, Multigated Acquisition Scan, Tumor Resection
- Procedure · Drug · Biological
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas